Larson Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Larson Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.7K	Sell	278 -2	-0.7%	-$140	﹤0.01%	1994
2026 Q1	$20.8K	Sell	280 -201	-42%	-$14.6K	﹤0.01%	1823
2025 Q4	$36.8K	Sell	481 -12	-2%	-$788	﹤0.01%	1400
2025 Q3	$25.6K	Buy	493 +109	+28%	+$5.32K	﹤0.01%	1502
2025 Q2	$16.6K	Buy	384 +200	+109%	+$7.27K	﹤0.01%	1573
2025 Q1	$6.36K	Buy	184 +1	+0.5%	+$34	﹤0.01%	1813
2024 Q4	$5.02K	Hold	183	–	–	﹤0.01%	1667
2024 Q3	$4.66K	Hold	183	–	–	﹤0.01%	1679
2024 Q2	$4.63K	Buy	+183	New	+$5K	﹤0.01%	1461
2023 Q3	–	Sell	-460	Closed	-$7.91K	–	1713
2023 Q2	$7.91K	Hold	460	–	–	﹤0.01%	1001
2023 Q1	$7.63K	Hold	460	–	–	﹤0.01%	993
2022 Q4	$3.5K	Hold	460	–	–	﹤0.01%	1101
2022 Q3	$5K	Hold	460	–	–	﹤0.01%	942
2022 Q2	$4K	Hold	460	–	–	﹤0.01%	889
2022 Q1	$5K	Buy	+460	New	+$4.72K	﹤0.01%	779
2021 Q4	–	Sell	-253	Closed	-$12K	–	1072
2021 Q3	$12K	Buy	+253	New	+$13.6K	﹤0.01%	548

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Larson Financial Group's BBIO Position: Q2 2026 in Review

Larson Financial Group reduced its BridgeBio Pharma (BBIO) stake by 0.71% in Q2 2026, selling an estimated $140 and leaving 278 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1994.

Larson Financial Group first reported a position in BBIO in Q3 2021 and has held it in 16 quarters since. The position peaked at $36.8K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Larson Financial Group held 278 shares of BridgeBio Pharma worth $20.7K as of Q2 2026.
Larson Financial Group sold 2 BridgeBio Pharma shares in Q2 2026, an estimated $140.
BridgeBio Pharma made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1994 holding.
Larson Financial Group first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 16 quarters since.
Larson Financial Group's BridgeBio Pharma position peaked at $36.8K in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.